Merck’s Recarbrio Shows Success in Late-Stage Trial for HABP/VABP Patients

Nicholas Kartsonis, head of clinical research in infectious diseases and vaccines at Merck Research Laboratories, noted that additional treatment options are needed for critically ill patients with respiratory infections.